Incurred sample reanalysis [Regulatives / Guidelines]

posted by The Outlaw Torn – Europe, 2013-04-10 10:40 (4435 d 20:22 ago) – Posting: # 10387
Views: 15,181

Dear Ohlbe,

❝ The long-term stability is not the only issue anyway: back-conversion during sample processing can be of greater concern. And are you sure you know all metabolites ? EMA got trapped in their recommendations on clopidogrel1


I just happened to be cruising by this joint looking for anything new on ISR. Glad to see you tapping this subject. You answered a lot of my questions, except I'm not sure I understand what you mean by the EMA getting trapped. Do you mean that there are ways around justifying clopidogrel, or other drugs known for back-conversion, that EMA hadn't considered (the paper you quoted where the authors found a way of controlling back-conversion)? Is that it? If that's not the case, mind expanding on this while I sit back and have a drink?

Thanks,
Outlaw

Complete thread:

UA Flag
Activity
 Admin contact
23,424 posts in 4,927 threads, 1,678 registered users;
20 visitors (0 registered, 20 guests [including 15 identified bots]).
Forum time: 07:02 CEST (Europe/Vienna)

EMEA. The European Medicines Evaluation Agency.
The drug regulatory agency of the European Union.
A statistician-free zone.    Stephen Senn

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5